BEIJING - More than 70 public figures have signed a petition opposing an application for listing on the Shenzhen Stock Exchange submitted by a pharmaceutical company that makes medicine from bear bile. The company, Guizhentang Pharmaceuticals, extracts bile from captive bears to make traditional Chinese medicines. Founded in 2000, the company is among 220 awaiting approval by the Growth Enterprise Board, according to the China Securities Regulatory Commission.
We first published details about the APT in our Jan 2010 M-Trends report... Our position was that “The Chinese govt may authorize this activity, but there’s no way to determine the extent of its involvement.” Now, three years later, we have the evidence required to change our assessment. The details we have analyzed during hundreds of investigations convince us that the groups conducting these activities are based primarily in China and that the Chinese Government is aware of them.